Article
Pharmacogenetics-Guided Phase I Study of Capecitabine on an Intermittent Schedule in Patients with Advanced or Metastatic Solid Tumours.
Scientific reports - 14 Jun 2016
Soo Ross Andrew, Syn Nicholas, Lee Soo-Chin, Wang Lingzhi, Lim Xn-Yii, Loh Marie, Tan Sing-Huang, Zee Ying-Kiat, Wong Andrea Li-Ann, Chuah Benjamin, Chan Daniel, Lim Siew-Eng, Goh Boon-Cher, Soong Richie, Yong Wei-Peng
Abstract excerpt
The FDA-approved starting dosage of capecitabine is 1,250 mg/m(2), and market research indicates that U.S. physicians routinely prescribe 1,000 mg/m(2). Retrospective analyses however report reduced toxicity and efficacy in a subset of patients with the 3R/3R genotype of the thymidylate synthase gene enhancer region (TSER). This study sought to develop TSER genotype-specific guidelines for capecitabine dosing....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.